Iconix Pharmaceuticals, Inc. Study Drives Methods For Discovering And Validating Predictive Toxicology Biomarkers  
6/23/2006 1:44:48 PM

MOUNTAIN VIEW, Calif., June 23 /PRNewswire/ -- Iconix Pharmaceuticals, Inc. today announced that a study by Iconix scientists on the use of genomic data to find biomarkers to predict adverse effects of drug candidates has received the "Best Paper of 2005" award from the well known industry journal Toxicologic Pathology. The paper describes the discovery of a key biomarker that predicts kidney toxicity weeks in advance of its occurrence, something that is not possible with current toxicological methods. By providing all the information required to enable other laboratories to further validate the biomarker, the paper also addresses issues about the use of genomic biomarkers that were raised in the FDA's "Guidance for Industry: Pharmacogenomic Data Submissions," issued last year.